Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed US-based pharmaceutical company.
The deal is valued at 737.3 billion won and is valid till December 2031, the contract development and manufacturing organization said in a regulatory filing on Monday with Korea Exchange.
Shares of Samsung Biologics rose nearly 1% in recent trade on Tuesday, April 29.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.